22 reports

  • PROJECTED PREVALENCE OF CVDS IN US
  • Advance its product pipeline through increased investment in R&D activities

About Myocardial Infarction Drugs Myocardial infarction, commonly known as heart attack, is the irreparable death of the heart tissue. It occurs when blood stops flowing to a part of the myocardium (heart muscle), depriving it of oxygen and nutrients. If the coronary artery that supplies blood to the heart muscle is blocked by the formation...

  • Heart Attack
  • AstraZeneca PLC
  • Novartis AG
  • NSTEMI group
  • Pfizer Inc.
  • 5.1 CARDIOVASCULAR TESTING

The ideal AMI marker is one that has high clinical sensitivity and specificity, appears soon after the onset of a heart attack; remains elevated for several days following a heart attack and can be assayed with a rapid turnaround time.

  • Heart Attack
  • Abbott Laboratories, Inc.
  • Alere Inc.
  • Beckman Coulter, Inc.
  • Boditech Med Inc.

Heart Attack - Pipeline Review, H## 2015 Table of Contents Table of Contents ## List of Tables ## List of Figures ## Introduction ## Global Markets Direct Report Coverage ## Heart Attack Overview ## Therapeutics Development ## Pipeline Products for Heart

  • Chronic Disease
  • Heart Attack
  • Therapy
  • World
  • Aug 27, 2017: Anti-inflammatory drug could reduce risk of second heart attack
  • Jun 22, 2017: Novartis Phase III study shows ACZ885 reduces cardiovascular risk in people who survived a heart attack

Interleukin 1 (IL1) - Pipeline Review, H2 2017 Summary Interleukin 1 (IL1) - Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of...

  • Chronic Disease
  • Heart Attack
  • Therapy
  • United States
  • Product Initiative

Heart Attack - Pipeline Review, H## 2015 Table of Contents Introduction ## Global Markets Direct Report Coverage ## Heart Attack Overview ## Therapeutics Development ## Pipeline Products for Heart Attack - Overview ## Pipeline Products for

  • Chronic Disease
  • Heart Attack
  • Pharmaceutical
  • Therapy
  • World
  • Feb 07, 2018: Brilinta significantly reduces CV events and coronary death beyond one year in heart attack survivors with multi-vessel disease
  • LATEST CLINICAL TRIALS NEWS ON MYOCARDIAL INFARCTION

Myocardial Infarction Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Myocardial Infarction Global Clinical Trials Review, H1, 2018" provides an overview of Myocardial Infarction clinical trials scenario.This report provides top line data relating to the clinical...

  • Cardiovascular Disease
  • Clinical Trial
  • Heart Attack
  • Hospital
  • World
  • SMALL MOLECULE FOR REPERFUSION INJURY AND HEART ATTACK - DRUG PROFILE
  • Feb 02, 2017: Positive Preliminary Data from Preclinical Heart Attack Study with Cynata's MSCs

Myocardial Infarction - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Infarction - Pipeline Review, H1 2018, provides an overview of the Myocardial Infarction (Cardiovascular) pipeline landscape. Myocardial infarction...

  • Cell Therapy
  • Heart Attack
  • United States
  • World
  • Product Initiative
  • SMALL MOLECULE FOR REPERFUSION INJURY AND HEART ATTACK - DRUG PROFILE
  • Jun 14, 2016: Thymosin Beta 4 Effective in Treatment of Heart Attack Patients

Myocardial Infarction - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Infarction - Pipeline Review, H2 2017, provides an overview of the Myocardial Infarction (Cardiovascular) pipeline landscape. Myocardial infarction is the irreversible...

  • Chronic Disease
  • Heart Attack
  • United States
  • Product Initiative
  • Athersys, Inc.
  • DIAGNOSTIC BLOOD TEST - HEART ATTACK - PRODUCT STATUS
  • DIAGNOSTIC BLOOD TEST - HEART ATTACK - PRODUCT DESCRIPTION

Troponin Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 Summary GlobalData’s Medical Devices sector report, “Troponin Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Troponin Diagnostic Tests currently in pipeline stage. The report provides comprehensive information...

  • Clinical Trial
  • Diagnostics
  • Heart Attack
  • Immunochemistry Test
  • GlobalData's company
  • JUN 01, 2015: NEUROVIVE REPORTS TOPLINE RESULTS OF PHASE III CIRCUS STUDY IN ACUTE MYOCARDIAL INFARCTION
  • MAY 25, 2015: NEUROVIVE PHARMACEUTICAL: TOPLINE RESULT OF PHASE III STUDY OF CICLOMULSION IN ACUTE MYOCARDIAL INFARCTION EXPECTED THIS QUARTER

Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin...

  • Heart Attack
  • Therapy
  • World
  • Product Initiative
  • CicloMulsion AG

SCAD is the number one cause of heart attacks in young women## and the average age is ##.

  • Cardiology
  • Cardiovascular Disease
  • Heart Attack
  • Hospital
  • Abiomed, Inc.
  • MIRACOR MEDICAL SYSTEMS GMBH COMPANY SNAPSHOT
  • RECENT DEVELOPMENTS

Summary Miracor Medical Systems GmbH (Miracor Medical) is a medical device company that develops and commercializes pressure-controlled intermittent coronary sinus occlusions. The company offers products for continuous monitoring of coronary sinus pressure dynamics. It offers impulse console and impulse catheter,...

  • Heart Attack
  • United Kingdom
  • United States
  • Product Initiative
  • NSTEMI group

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiology
  • Clinical Trial
  • Heart Attack
  • Hospital
  • World

They are coming in with a heart attack.

  • Heart Attack
  • Therapy
  • United States
  • Product Initiative
  • Abbott Vascular, Inc.
  • Angion Biomedica Corp. - Recent Pipeline Updates, 2015
  • Product Description

The study will evaluate the effect of BB## to preserve myocardial (heart) tissue and function following myocardial infarction (heart attack).

  • Heart Attack
  • Therapy
  • United States
  • Product Initiative
  • Angion Biomedica Corp.
  • Clinical Trial profile. 678 Trial Title
  • Clinical Trial profile. 438 Trial Title

Myocardial Infarction Global Clinical Trials Review, H2, 2015 Summary GlobalData's clinical trial report, “Myocardial Infarction Global Clinical Trials Review, H2, 2015" provides an overview of Myocardial Infarction clinical trials scenario. This report provides top line data relating to the clinical trials on Myocardial...

  • Clinical Trial
  • Drug Discovery And Development
  • Heart Attack
  • Therapy
  • World
  • MAY 20, 2014: STENTYS SIROLIMUS-ELUTING STENT DEMONSTRATES BEST IN CLASS EFFICACY FOR HEART ATTACK PATIENTS
  • CID S.R.L. COMPANY OVERVIEW

Drug Eluting Stents (DES) - Pipeline Review, 2015 Summary GlobalData's Medical Devices sector report, “Drug Eluting Stents (DES) - Pipeline Review, 2015" provides an overview of Drug Eluting Stents currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative...

  • Clinical Trial
  • Drug Discovery And Development
  • Heart Attack
  • Interventional Cardiology Device
  • GlobalData's company
  • Clinical Trial profile. 38 Trial Title

Reperfusion Injury Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Reperfusion Injury Global Clinical Trials Review, H2, 2016" provides an overview of Reperfusion Injury clinical trials scenario. This report provides top line data relating to the clinical trials on Reperfusion Injury....

  • Cardiology
  • Drug Discovery And Development
  • Heart Attack
  • World
  • Product Initiative
  • Clinical Trial Profile Snapshots

The prominent features of this report are - ##.

  • Chronic Disease
  • Heart Attack
  • Therapy
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Cardiology
  • Heart Attack
  • Pharmaceutical
  • World
  • Product Initiative
  • Phase I - Trial Details

Research into CicloMulsion s efficacy beyond the treatment of reperfusion injury following heart attack grew out of the concept of mitochondrial protection in connection with organ injury focusing on heart disease.

  • Heart Attack
  • United States
  • World
  • Company Operations
  • Product Initiative

At the heart of Vereos is a state-of-the-art detector that converts detected photons directly into digital information.

  • Fetal Monitoring
  • Healthcare
  • Heart Attack
  • Magnetic Resonance Imaging
  • GlobalData's company